Prescription Topical Treatments
Topical treatments such as creams and ointments are often the first therapies recommended to treat psoriasis. Topical treatments primarily work by reducing inflammation and slowing down and regulating skin cell turnover. Topicals exist in many different forms, such as lotions, creams, ointments, foams, or shampoo. Depending on the location of psoriasis plaques on the body, a specific formulation may be better suited for treatment. Many topical medications require a prescription, but some do not. When psoriasis is more severe, topicals are likely to be combined with oral medications, phototherapy, or biologics.
List of Prescription Topical Treatments (Psoriasis)
Click on a medication for additional information.
- Topical corticosteroids (e.g., betamethasone & mometasone)
- Vitamin D3 analogues (Dovonex® & Silkis®)
- Combination vitamin D3 analogues & corticosteroids (Dovobet® & Enstilar™)
- Topical retinoids (Tazarotene)
- Anthralin & tars
- Halobetasol propionate and tazarotene (DUOBRII®)
- Halobetasol propionate lotion (Bryhali™)
- Roflumilast (ZORYVE™)
Topical Corticosteroids (e.g., betamethasone & mometasone)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
How Does It Work?
Corticosteroids applied topically have the ability to decrease inflammation in the skin in many conditions, including psoriasis.
How Is It Used?
Topical corticosteroids are typically prescribed to be applied to psoriatic plaques twice daily. Topical corticosteroids are available in a variety of different potencies (strengths). Your doctor may prescribe a certain strength topical corticosteroid depending on the thickness of psoriasis plaques and their location on your body.
What are the possible side effects?
The most common side effect of topical corticosteroids is an initial mild burning or stinging feeling after application. Long-term use of strong corticosteroids can result in thinning of the skin. This should be monitored by you and your physician.
Any Other Important Considerations?
Avoid covering the steroids with bandages or plastic wrap unless instructed to do so by your doctor.
What Medications Interact With This Treatment?
N/A
What Provinces and Territories List It On Formulary?
Varies depending on specific corticosteroid.
Product Monograph
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Vitamin D3 Analogues
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
How Does It Work?
Vitamin D3 analogues work by regulating skin cell production and proliferation (buildup), which is abnormal in psoriasis. Vitamin D3 analogues used to treat psoriasis include calcitriol (Silkis®) and calcipotriol (Dovonex®).
How Is It Used?
Vitamin D3 analogues are available as topical ointments and are applied as to the affected area of skin once or twice daily as directed by physician.
What are the possible side effects?
The most common side effect of vitamin D3 analogues is a temporary burning or stinging sensation when applied to the skin.
Any Other Important Considerations?
N/A
What Medications Interact With This Treatment?
N/A
| Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis |
|---|---|---|---|---|---|
| Nunavut | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
| Nunavut | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | No | N/A |
| Alberta | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
| Alberta | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | No | N/A |
| British Columbia | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
| British Columbia | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | No | N/A |
| Manitoba | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
| Manitoba | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | No | N/A |
| New Brunswick | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
| New Brunswick | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | Yes | N/A |
| Newfoundland and Labrador | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
| Newfoundland and Labrador | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | No | N/A |
| NIHB | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
| NIHB | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | No | N/A |
| Northwest Territories | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
| Northwest Territories | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | No | N/A |
| Nova Scotia | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes - EDS | N/A |
| Nova Scotia | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | Yes | N/A |
| Ontario | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes – L/U | N/A |
| Ontario | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | Yes – L/U | N/A |
| Prince Edward Island | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
| Prince Edward Island | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | No | N/A |
| Quebec | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
| Quebec | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | Yes | N/A |
| Saskatchewan | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
| Saskatchewan | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | No | N/A |
| Yukon | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcipotriol - Dovonex® | Yes | N/A |
| Yukon | Prescription Topical Treatments | Vitamin_D3_Analogues(Dovonex® Silkis®) | Calcitriol - Silkis® | Yes | N/A |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
Calcipotriol (Dovobet®_Gel): https://pdf.hres.ca/dpd_pm/00055197.PDF
Calcipotriol (Dovobet®_Ointment): https://pdf.hres.ca/dpd_pm/00034364.PDF
Enstilar™_Foam: https://pdf.hres.ca/dpd_pm/00065877.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Topical Retinoids (Tazarotene)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
How Does It Work?
The exact mechanism of tazarotene is unknown. It is thought to play a role in the differentiation of skin (i.e., it helps to control the multiplication of skin cells), and it may also help to regulate the immune system.
How Is It Used?
Tazarotene comes in both a gel and cream formulation. Typically, it is recommended to be applied to the affected area of skin once a day, usually at night. Improvement is typically noted within two months of treatment.
What are the possible side effects?
The most common side effect of topical retinoids is skin irritation. Redness, a burning sensation, dry skin, and skin shedding are commonly experienced with tazarotene, but these side effects tend to subside after a few weeks of treatment.
Any Other Important Considerations?
Tazarotene cannot be used during pregnancy.
Avoid unprotected exposure to sunlight and sunlamps as this product may increase the sensitivity of skin to ultraviolet light.
What Medications Interact With This Treatment?
No known significant drug interactions.
| Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis |
|---|---|---|---|---|---|
| Alberta | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes | N/A |
| British Columbia | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes | N/A |
| Manitoba | Prescription Topical Treatments | Topical Retinoids | Tazarotene | No | N/A |
| New Brunswick | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes – S/A | N/A |
| Newfoundland and Labrador | Prescription Topical Treatments | Topical Retinoids | Tazarotene | No | N/A |
| NIHB | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes | N/A |
| Northwest Territories | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes | N/A |
| Nova Scotia | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes – EDS | N/A |
| Nunavut | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes | N/A |
| Ontario | Prescription Topical Treatments | Topical Retinoids | Tazarotene | No | N/A |
| Prince Edward Island | Prescription Topical Treatments | Topical Retinoids | Tazarotene | No | N/A |
| Quebec | Prescription Topical Treatments | Topical Retinoids | Tazarotene | No | N/A |
| Saskatchewan | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes | N/A |
| Yukon | Prescription Topical Treatments | Topical Retinoids | Tazarotene | Yes | N/A |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs. NIHB stands for non-insured health benefits. This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
Tazorac 0.05% Gel (tazarotene): https://pdf.hres.ca/dpd_pm/00031077.PDF
Tazorac 0.1% Gel (tazarotene): https://pdf.hres.ca/dpd_pm/00031077.PDF
Tazorac 0.05% Cream (tazarotene): https://pdf.hres.ca/dpd_pm/00033182.PDF
Tazorac 0.1% Cream (tazarotene): https://pdf.hres.ca/dpd_pm/00033182.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Anthralin & Tars
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
How Does It Work?
The exact mechanism of anthralin and tars are unknown but they are thought to decrease the skin inflammation that is associated with psoriasis. Coal tar loosens and softens scales and crusts.
How Is It Used?
Anthralin:
Generally applied once daily or as directed by a doctor or pharmacist. When first starting to use anthralin, a short contact time of 5 – 10 minutes of the cream may be advised during the first week of treatment. Contact time can be gradually increased to up to 30 minutes, as tolerated by the skin. Anthralin can be removed by washing or showering.
When applying, gloves may be used to avoid staining of fingers and nails. Apply directly to plaques; rub in gently and avoid application to unaffected skin. Petroleum jelly may be used around the edges of the plaque to prevent irritation of unaffected skin.
Coal tar:
For scalp psoriasis, coal tar may be painted sparingly to the lesions 3-12 hours before shampooing.
For body psoriasis, apply coal tar to the lesions at bedtime.
Wash hands before and after application.
What are the possible side effects?
Anthralin: temporary skin irritation, temporary hair discolouration, temporary nail discolouration, temporary skin discolouration.
Coal tar: temporary skin irritation, increased skin sensitivity to light.
Any Other Important Considerations?
Anthralin is irritating to surrounding normal skin. It also stains skin and fabrics.
Coal tar has an odour and can stain skin and hair.
What Medications Interact With This Treatment?
N/A
What Provinces and Territories List It On Formulary?
N/A
Product Monograph
N/A
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Halobetasol propionate and tazarotene (DUOBRII®)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
How Does It Work?
DUOBRII® is a lotion used on the skin to improve the signs and symptoms of psoriasis in adults.
DUOBRII® is a combination of two different medications. It contains halobetasol propionate, a corticosteroid, and tazarotene, a topical retinoid. Halobetasol propionate has the ability to decrease inflammation in the skin. Tazarotene is thought to work by helping with the normal growth of skin cells and by reducing inflammation.
How Is It Used?
Apply a thin layer once a day to affected skin. Rub in gently and wash your hands after application. Once your psoriasis is better, stop using DUOBRII® . It may then be used on and off as necessary, or as directed by your physician.
What are the possible side effects?
The most common side effects include contact dermatitis, a skin rash, or sores. Please consult the Product Monograph for more side effects.
Prolonged use of this product may cause the adrenal glands to become suppressed. Only use DUOBRII® under the supervision of a physician.
Any Other Important Considerations?
Do not use DUOBRII® :
- If you are allergic to halobetasol propionate, tazarotene or any of the other ingredients found in DUOBRII®.
- If you are allergic to other corticosteroids or retinoic compounds.
- On some other skin conditions (such as dermatitis, skin reactions after a vaccine, and infections).
- If you are pregnant or if you think you might be pregnant.
What Medications Interact With This Treatment?
No known significant drug interactions.
| Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis |
|---|---|---|---|---|---|
| Alberta | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes - S/A | N/A |
| British Columbia | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | No | N/A |
| Manitoba | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A |
| New Brunswick | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A |
| Newfoundland and Labrador | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes – S/A | N/A |
| NIHB | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A |
| Northwest Territories | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A |
| Nova Scotia | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | No | N/A |
| Nunavut | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A |
| Ontario | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A |
| Prince Edward Island | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | No | N/A |
| Quebec | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes - S/A | N/A |
| Saskatchewan | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | Yes | N/A |
| Yukon | Prescription Topical Treatments | Halobetasol propionate and tazarotene | DUOBRII® | No | N/A |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
https://pdf.hres.ca/dpd_pm/00066402.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Halobetasol propionate lotion (Bryhali™)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
How Does It Work?
Bryhali is a topical steroid, meaning it stops inflammation in areas that it is applied to which is helpful in treating plaque psoriasis.
How Is It Used?
Bryhali is a cream that is applied to areas of skin affected by plaque psoriasis. Bryhali should typically not be used for more than 8 weeks. There are several areas of the skin Bryhali should not be applied to because of risk of skin damage, so always talk to your doctor prior to using Bryhali to establish the appropriate amount to use and appropriate area of use.
What are the possible side effects?
Possible side effects of Bryhali include reaction of the skin the cream is applied to, including change in appearance of the skin as well as burning or itching skin. Less common side effects include increased risk of infection, cough, and high blood pressure. To obtain a comprehensive list of all potential side effects, talk to your doctor or pharmacist.
Any Other Important Considerations?
Bryhali should typically not be used for more than 8 weeks. Bryhali should typically be used with caution if you have any skin infections or history of high blood pressure.
What Medications Interact With This Treatment?
There are no known drug interactions with Bryhali, but always check with your doctor prior to starting Bryhali to rule out any possibility of drug interaction.
| Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
https://pdf.hres.ca/dpd_pm/00060714.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Roflumilast (ZORYVE™)
- How Does It Work?
- How Is It Used?
- Side Effects?
- Important Considerations?
- Interactions?
- Public Drug Program Formulary Tables
- Product Monograph
How Does It Work?
Roflumilast is a non-steroid selective inhibitor of phosphodiesterase 4 (PDE4), used for the topical treatment of plaque psoriasis, including treatment of psoriasis in the intertriginous areas, in patients 12 years of age and older.
How Is It Used?
Apply roflumilast topically once a day to affected areas of the skin and rub in completely. Wash hands after application unless hands are the affected areas being treated.
If deemed medically necessary to use during breast-feeding, use roflumilast on the smallest area of the skin for the shortest duration possible. Do not apply roflumilast directly to the nipple and areola to avoid direct infant exposure.
Roflumilast is for topical use only and not for ophthalmic, oral, or intravaginal use.
What are the possible side effects?
The most common adverse drug reactions reported in clinical trials among patients with plaque psoriasis 12 years of age and older are diarrhea and headache. To obtain a comprehensive list of all known potential side effects of roflumilast, talk to your doctor or pharmacist.
Any Other Important Considerations?
Roflumilast is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C), and patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredients, or components of the container.
Roflumilast should not be used during labor and delivery. Roflumilast should only be used by a breast-feeding mother if deemed medically necessary, considering a potential risk to the baby. To minimize potential exposure to the breastfed infant via breast milk, use roflumilast on the smallest area of skin and for the shortest duration possible while breastfeeding. Do not to apply roflumilast directly to the nipple and areola to avoid direct infant exposure.
What Medications Interact With This Treatment?
No formal drug-drug interaction studies were conducted with roflumilast. For a complete list of medications that may interact with roflumilast and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.
| Province | Class | Generic Name | Drug Name | Psoriasis | Psoriatic Arthritis |
More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.
NIHB stands for non-insured health benefits.
This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.
Product Monograph
https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102624
https://pdf.hres.ca/dpd_pm/00070453.PDF
The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.
This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.
Last updated May 31, 2024.
Disclaimer
This Site was designed for educational purposes only and not for the purpose of rendering medical advice. Individual variances in psoriasis cases require the consultation of a physician to make sound medical decisions. The information presented on this website is not intended to replace the counsel of your physician. It is important to see your doctor before altering anything in your treatment plan. The Canadian Psoriasis Network does not endorse any medications, products, equipment or treatments for psoriasis and psoriatic arthritis. Any of the information contained within the Canadian Psoriasis Network’s Site is not presented as a substitute for informed medical advice. Visitors to this site should not engage in self-diagnosis nor act on information contained in the Site without seeking specific advice on the particular matters which are of concern to them from qualified health professionals and advisors. Some of the information contained in the Site has been provided from external sources. While efforts have been made to ensure the accuracy, currency, and reliability of the content, the Canadian Psoriasis Network accepts no responsibility in that regard. Please refer to our Terms of Use for further details.
This resource was made possible through support from:
